Quick Answer
A structured infertility workup at the first visit evaluates both partners simultaneously — not the woman first and the man if she’s “normal.” Male factor accounts for approximately 40–50% of infertility presentations. The core first-visit assessment covers: female — menstrual history, ovulation status (LH surge, Day 21 progesterone, ultrasound), ovarian reserve (AMH or Day 2-3 FSH), and uterine/tubal cavity assessment; male — structured semen analysis interpreted against WHO 2021 reference values. Investigations can typically be initiated before a formal specialist referral is made. Referral thresholds vary by duration of infertility, female age, and findings — this article covers each in a structured format.
Most Indian clinical content on infertility focuses exclusively on the woman. Investigations are ordered for her, imaging is done for her, and the history is taken almost entirely about her cycles. The male partner receives a semen analysis only if her evaluation comes back normal — or sometimes not at all if she has an identifiable diagnosis like PCOS or fibroids.
This approach is clinically wrong in approximately half of all infertility presentations. Male factor contributes to infertility in 40–50% of couples — either as the sole cause or in combination with a female factor. A workup that doesn’t evaluate the male partner at the first visit is missing the cause of infertility in every other case.
This article sets out a structured first-visit infertility workup that evaluates both partners systematically, covers the key investigations, sets realistic referral thresholds, and includes the commonly missed elements of a complete assessment. Doctors who want structured training in managing infertility at a clinical level can explore MGA’s Fellowship in Infertility Management.
What this article covers
- Defining infertility — when to investigate
- The female partner workup — history, ovulation, ovarian reserve, anatomy
- The male partner workup — history, semen analysis interpretation
- Investigations summary — what to order at first visit
- Commonly missed elements of the infertility workup
- Referral thresholds — when to refer and to whom
- Frequently asked questions
Defining infertility — when to investigate
The standard clinical definition of infertility is the failure to achieve a clinical pregnancy after 12 months of regular unprotected intercourse. This 12-month threshold applies to women under 35 years of age. For women aged 35 or older, the threshold for investigation shortens to 6 months — because ovarian reserve declines with age and delay reduces the available treatment window.
Some presentations justify earlier investigation regardless of duration:
- Known or suspected ovulatory dysfunction (oligomenorrhoea, amenorrhoea)
- Known or suspected tubal factor (previous PID, ectopic pregnancy, pelvic surgery)
- Known uterine pathology (fibroids, previous uterine surgery, Asherman’s syndrome)
- Known or suspected male factor (previous testicular surgery, mumps orchitis, azoospermia)
- Female age ≥38 — do not wait 6 months, investigate immediately
The female partner workup
History — what to cover systematically
A structured infertility history covers: duration of infertility and whether this is primary or secondary; menstrual cycle pattern (cycle length, regularity, flow, dysmenorrhoea); previous pregnancies and their outcomes; contraceptive history (including IUD use and duration); previous gynaecological procedures (D&C, hysteroscopy, laparoscopy, Caesarean section); symptoms of ovulatory dysfunction (intermenstrual spotting, cycle irregularity, galactorrhoea); and symptoms of PCOS, thyroid disease, or hyperprolactinaemia.
Ovulation assessment
Regular cycles of 25–35 days occurring consistently are a reasonable clinical indicator of ovulation in most women — but not a guarantee. Formal ovulation assessment options:
| Method | Timing | Interpretation | Limitation |
|---|---|---|---|
| Mid-luteal progesterone | Day 21 in 28-day cycle; 7 days before expected period in irregular cycles | ≥5 ng/mL suggests ovulation; ≥10 ng/mL more reliable indicator | Timing errors common if cycle irregular |
| LH surge (urine OPK) | Starting from Day 10–12 in typical cycle | Surge detected 24–36 hours before ovulation | False positives in PCOS (multiple LH peaks) |
| Follicular tracking ultrasound | Serial scans from Day 8–10 | Dominant follicle development and collapse confirms ovulation | Requires multiple visits; resource-intensive in primary care |
| Day 2-3 FSH/LH | Day 2–4 of cycle | Elevated FSH indicates diminished ovarian reserve; high LH:FSH ratio suggests PCOS | Single-cycle snapshot; inter-cycle variability exists |
Ovarian reserve assessment
Ovarian reserve testing estimates the remaining primordial follicle pool and predicts ovarian response to stimulation. Two primary tests:
- AMH (Anti-Müllerian Hormone): Can be measured on any day of the cycle. AMH ≥1.0 ng/mL generally indicates adequate ovarian reserve; AMH <1.0 ng/mL suggests diminished reserve. AMH <0.5–0.7 ng/mL (laboratory-specific thresholds vary) indicates severely diminished reserve requiring earlier specialist referral.
- Antral Follicle Count (AFC): Transvaginal ultrasound on Day 2–4 counting follicles 2–10 mm in each ovary. Total AFC <5–7 suggests diminished reserve; AFC >20 raises OHSS risk in stimulation cycles. AFC is operator-dependent and may not be feasible in a general practice setting.
Uterine and tubal assessment
Baseline pelvic ultrasound: Assess uterine size, shape, and myometrium (fibroids, adenomyosis features), endometrial thickness and pattern in relation to cycle phase, and ovarian morphology (AFC, PCO pattern, ovarian cysts). This is the first-line uterine assessment tool available in most OBGYN practices.
Tubal patency: A blocked or damaged tube is a significant fertility factor that a basic pelvic ultrasound will not reveal. Standard options:
- HyCoSy (Hysterosalpingo-Contrast Sonography): Ultrasound-based tubal assessment using contrast agent. Acceptable sensitivity for tubal patency; avoids radiation; requires operator experience.
- HSG (Hysterosalpingogram): Fluoroscopic or digital X-ray with contrast — provides uterine cavity outline and tubal patency. Standard referral-level investigation where laparoscopy is not the first step. Note: false positive rates for tubal spasm exist — confirm before proceeding to surgical treatment.
- Diagnostic laparoscopy: Gold standard for tubal and peritoneal assessment — direct visualisation of tubes, peritoneum, and endometriosis. Reserved for cases where pelvic pathology is clinically suspected or HSG is inconclusive.
Endocrine investigations: Day 2-3 FSH, LH, E2, prolactin, TSH, and AMH as discussed. Add testosterone, DHEAS, and 17-OHP where PCOS or androgen excess is suspected.
The male partner workup
The male partner evaluation must happen at the first visit — not as a fallback after female investigations. The reason is not merely philosophical: male factor is present in up to 50% of infertile couples, and the result of the semen analysis directly determines the management pathway for the couple.
History — what to cover for the male partner
- Previous pregnancies with current or previous partner
- Sexual history — erectile function, ejaculation, frequency of intercourse
- Developmental history — cryptorchidism, orchidopexy, age of puberty
- Previous testicular trauma, torsion, or infection (mumps orchitis)
- Previous urogenital surgery — vasectomy, hernia repair, hydrocelectomy
- Systemic illness — diabetes, hypertension, chronic kidney disease
- Medications — antihypertensives (calcium channel blockers reduce sperm function), anabolic steroids (suppress HPO axis and spermatogenesis), antidepressants, antipsychotics
- Occupational or environmental exposures — heat (extended sitting, laptop use, occupational heat exposure), pesticides, heavy metals
- Lifestyle — smoking, alcohol, recreational drug use, BMI
Semen analysis — interpretation using WHO 2021 reference values
The WHO 2021 (6th edition) lower reference limits represent the 5th centile values from fertile men. The key change from the 2010 5th edition is a reduction in the lower reference limit for total motile sperm count, among other parameters.
| Parameter | WHO 2021 Lower Reference Limit | Clinical Note |
|---|---|---|
| Volume | 1.4 mL | Low volume with normal sperm suggests ejaculatory duct obstruction or retrograde ejaculation |
| Concentration | 16 million/mL | <5 million/mL is severe oligozoospermia; 0 = azoospermia |
| Total motility (PR+NP) | 42% | Progressive motility (PR) more clinically relevant than total motility |
| Progressive motility (PR) | 30% | Isolated asthenozoospermia — consider sperm DNA fragmentation |
| Morphology (Kruger strict) | 4% normal forms | Isolated teratozoospermia — IUI has limited utility; IVF/ICSI more appropriate |
| Total motile sperm count | 12 million | Best single predictor of treatment outcome in ART |
| Vitality | 54% live | Low vitality with poor motility = necrozoospermia — consider oxidative stress |
Key practice point: A single abnormal semen analysis must be confirmed with a second analysis after 2–3 months (one full spermatogenic cycle). Semen quality has significant intra-individual variability — one result below reference limits, particularly for concentration, does not constitute a confirmed diagnosis of male factor infertility. Exception: azoospermia confirmed on two analyses or severe oligozoospermia (<1 million/mL) should trigger prompt specialist referral without waiting for a third cycle.
Investigations summary — what to order at the first visit
| Investigation | Partner | Timing | What It Answers |
|---|---|---|---|
| Semen analysis | Male | Any time; 2–5 day abstinence | Male factor present or absent |
| Day 2-3 FSH, LH, E2, Prolactin, TSH | Female | Day 2–4 of menstrual cycle | Ovarian reserve baseline, pituitary function, prolactin, thyroid |
| AMH | Female | Any day of cycle | Ovarian reserve assessment |
| Mid-luteal progesterone | Female | Day 21 (or 7 days before expected period) | Confirms ovulation |
| Pelvic ultrasound (transvaginal) | Female | Early follicular phase preferred (Day 2–5) | Uterine anatomy, ovarian morphology, AFC, pelvic pathology |
| HSG or HyCoSy | Female | Follicular phase (before ovulation) | Tubal patency and uterine cavity outline |
Commonly missed elements of the infertility workup
| Missed Element | Why It’s Missed | Clinical Consequence |
|---|---|---|
| Male partner evaluation at first visit | Cultural assumption that infertility is a female problem; male partner doesn’t accompany female to first visit | Male factor missed for months; female treated unnecessarily |
| TSH in the female | Not part of many standard infertility panels; thyroid disease considered separately | Subclinical hypothyroidism missed — treatable cause of ovulatory dysfunction and implantation failure |
| Prolactin | Assumed normal if there’s no galactorrhoea | Hyperprolactinaemia can cause anovulation without galactorrhoea — easily treatable |
| Confirmation of semen analysis | Single abnormal result acted on immediately | Treatment escalation based on a transient finding; significant intra-individual variability |
| Tubal assessment | Skipped in the absence of PID history or pelvic pain | Silent tubal disease missed — Chlamydia serology positive in 10–20% of women without a clear PID history |
| Intercourse frequency and timing | Embarrassment; assumed adequate | Couples with infrequent intercourse or significant timing errors may respond to simple advice before investigations |
Referral thresholds — when to refer and to whom
The appropriate referral decision depends on duration of infertility, female age, and investigation findings — not on a fixed rule that all infertile couples should be referred immediately.
Refer to a fertility specialist when:
- Duration threshold reached: 12 months trying in women under 35; 6 months in women 35–37; immediately in women 38 and above
- Confirmed anovulation not responding to first-line ovulation induction (3–6 cycles of letrozole or clomiphene with no conception)
- Severe male factor: Azoospermia on two analyses, or total motile sperm count <1 million
- Bilateral tubal occlusion on HSG or HyCoSy — IVF is the appropriate treatment, not repeated OI or IUI
- Diminished ovarian reserve (AMH <0.7 ng/mL or AFC <5) — IVF timing is important and delay reduces options
- Significant uterine pathology requiring surgical assessment (submucous fibroids, suspected Asherman’s, uterine septum)
Refer to andrology for male partner when:
- Azoospermia (confirmed on two samples) — requires clinical examination, FSH/LH/testosterone, and assessment for obstructive versus non-obstructive cause
- Severe oligozoospermia (<5 million/mL) — karyotype, Y-chromosome microdeletion testing
- Clinical varicocele with abnormal semen parameters — varicocelectomy may improve parameters
- Retrograde ejaculation or ejaculatory dysfunction
Build structured expertise in infertility management
MGA’s Fellowship in Infertility Management · ART · OI · IVF protocols · 12 months online
Related articles and programs
Frequently asked questions
When should a couple be investigated for infertility?
After 12 months of regular unprotected intercourse in women under 35. After 6 months in women aged 35–37. Immediately in women aged 38 and above, or in couples where a cause is already known or suspected (anovulation, previous PID, cryptorchidism, etc.).
Should I investigate both partners at the first visit?
Yes. Male factor contributes to infertility in approximately 40–50% of couples and is the sole cause in around 20%. Ordering a semen analysis at the first visit while simultaneously initiating the female evaluation is both clinically appropriate and time-efficient — waiting for the female workup to come back before assessing the male partner delays the diagnosis by several weeks in the cases where male factor is the primary or contributing problem.
What is the correct interpretation of a semen analysis?
Use the WHO 2021 (6th edition) reference values. A result below the lower reference limit on a single analysis requires confirmation with a second analysis after 2–3 months. Total motile sperm count is the most clinically useful single parameter for predicting treatment success. Azoospermia confirmed on two samples should prompt urgent andrology referral.
When should a semen analysis be confirmed?
Any abnormal semen analysis (other than confirmed azoospermia on two samples) should be repeated after 2–3 months — one full spermatogenic cycle. Semen quality shows significant intra-individual variability from factors including recent illness, fever, stress, and abstinence duration. A management decision based on a single abnormal result risks unnecessary treatment escalation.
Is tubal assessment necessary in all couples?
In couples without a clinical history of PID, previous ectopic pregnancy, or pelvic surgery, tubal assessment is still important before initiating ovulation induction or IUI. Undiagnosed tubal disease in a couple undergoing multiple OI or IUI cycles represents both wasted time and inappropriate treatment — IVF is the correct treatment for bilateral tubal occlusion, not OI or IUI.
Medical Global Academy — Editorial Team
This article is produced for educational purposes by MGA’s academic team. It provides a clinical reference overview for practising doctors and does not replace formal clinical training, specialist assessment, or institutional guidelines. WHO reference values cited are from the WHO Laboratory Manual for the Examination and Processing of Human Semen, 6th edition (2021). Last reviewed: August 2026.